Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03070093 | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Apr 20, 2021 | clinicaltrials |
| NCT03723135 | Expanded Access for CC-486 | approved for marketing | — | — | CelgeneINDUSTRY | 1 |
| Sep 18, 2020 |
| clinicaltrials |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | approved for marketing | — | — | Agios Pharmaceuticals, Inc.INDUSTRY | 0 | Jul 24, 2018 | clinicaltrials |
| NCT01869803 | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | approved for marketing | — | — | Wake Forest University Health SciencesOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01592136 | Expanded Access Program of Ponatinib | approved for marketing | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 20, 2021source: clinicaltrials